Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intermittent sunitinib in advanced solid tumors
NL-OMON20988Phase 1Recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sunitinib in Nonhematologic neoplasms (2 arms), sponsored by Amsterdam UMC, location VUmc. Primary endpoints: Maximum tolerated dose and Safety and tolerability. Started Jul 2013; status: recruiting.
02
Drugs
sunitinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON20988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20988.